Mithu
☆    

India,
2019-09-30 07:42

Posting: # 20651
Views: 189
 

 SUPAC level 3 changes for MR formulations [Regulatives / Guidelines]

Dear All,

My questions are on SUPAC IR and MR guidance about the conduction of BE study due to change in manufacturing site change:

1. IR product if we change the manufacturing site, do we need to perform BE study as suggested in SUPAC guidance for IR? or it would be okay to justify based on in vitro data?
2. For MR product SUPAC MR guidance is not clear for any requirement of conducting BE study. where as we do perform Fasting for such changes in manufacturing site change. are we doing correct?

regards,

Mithu.
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,885 posts in 4,214 threads, 1,366 registered users;
online 7 (0 registered, 7 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 01:34 CEST

The real purpose of the scientific method is to make sure
nature hasn’t misled you into thinking you know something
you actually don’t know.    Robert M. Pirsig

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5